J. Vanakoski et al., 150 MG FLUCONAZOLE DOES NOT SUBSTANTIALLY INCREASE THE EFFECTS OF 10 MG MIDAZOLAM OR THE PLASMA MIDAZOLAM CONCENTRATIONS IN HEALTHY-SUBJECTS, International journal of clinical pharmacology and therapeutics, 33(9), 1995, pp. 518-523
Fluconazole, an azole antifungal agent, moderately inhibits the CYP3A-
mediated metabolism of midazolam in vitro. We therefore studied whethe
r such an interaction takes place in vivo following oral administratio
n of these drugs, given as relevant double blinded doses in capsule fo
rm. In study I parallel groups of healthy subjects received oral midaz
olam 10 mg (MLD 10) or 15 mg (MID 15), placebo, or MID 10 mg + 150 mg
fluconazole (FLU) given 2 h earlier. Objective and subjective performa
nce tests were made before, and 30 and 90 min after the intake of mida
zolam. MID 10 and MID 15 moderately impaired performance on digit symb
ol substitution,letter cancellation and flicker fusion tests, and visu
al analogue scales revealed mild sedation. FLU + MID 10 had similar or
slightly stronger effects than MID 10; it differed from MID 10 in tha
t it lowered the flicker fusion threshold and produced subjective slow
ness and overall impairment. In study II 5 subjects received MID 10 af
ter placebo, after FLU, and after 750 mg erythromycin (ERY) at 1-week
intervals, following a crossover and double-blinded study design. Bloo
d was sampled before MID intake and 30, 60 and 90 min after it, and pe
rformance was measured. FLU acid ERY increased the effect of MID on fl
icker fusion and letter cancellation performances, and increased the H
PLC-assayed plasma midazolam (ERY + 100%, FLU + 50%) in comparison to
that measured after MID ingested alone. When the concentrations of mid
azolam together with its active metabolite alpha-OH-midazolam were ass
ayed by radioreceptor technique the increases caused by ERY and FLU we
re less and compatible with the pharmacodynamic data. We conclude that
oral 150 mg fluconazole increases the effects of midazolam slightly,
hardly to a clinically meaningful extent. The active metabolite of mid
azolam may confound the relevance of moderate increases in plasma mida
zolam concentrations.